Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07860957
NA

Midday Bright Light Therapy for Bipolar Depression

Sponsor: Istanbul University - Cerrahpasa

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled study evaluated adjunctive midday bright light therapy in adults with bipolar I or II disorder experiencing mild-to-moderate depression. Participants received either 10,000-lux bright light or 1,500-lux placebo light at home for 30 minutes daily between 12:00 PM and 2:00 PM for four weeks while continuing unchanged pharmacological treatment. The primary outcome was remission at week 4, defined as a total score below 9 on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version. Secondary outcomes included clinical status, psychosocial functioning, sleep quality, circadian characteristics, and adverse effects.

Official title: Midday Bright Light Therapy for Bipolar Depression: A Randomized, Double-Blind, Placebo-Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

37

Start Date

2021-04-01

Completion Date

2026-06-11

Last Updated

2026-10-13

Healthy Volunteers

No

Interventions

DEVICE

Bright Light Therapy

Bright light therapy was administered using a Beurer TL100 daylight therapy lamp (Beurer, Ulm, Germany) set to deliver 10,000 lux. Participants used the device at home for 30 minutes daily between 12:00 PM and 2:00 PM for four weeks, at a distance of 10 cm from the device. Participants were instructed to keep their face turned toward the light box while avoiding direct and continuous gaze at the light source.

DEVICE

Placebo Light Therapy

Placebo light therapy was administered using the same Beurer TL100 daylight therapy lamp (Beurer, Ulm, Germany) set to deliver 1,500 lux. Participants used the device at home for 30 minutes daily between 12:00 PM and 2:00 PM for four weeks, at a distance of 10 cm from the device, following the same instructions as the active treatment group.

Locations (2)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine

Istanbul, Turkey (Türkiye)

Bakırköy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology and Neurosurgery

Istanbul, Turkey (Türkiye)